Evidence map›Paper›PMID 36405722›Full record

ArticleFrontiers in immunology2022

Moving the needle: Employing deep reinforcement learning to push the boundaries of coarse-grained vaccine models.

Jonathan G Faris, Daniel Orbidan, Charles Wells, Brenden K Petersen, Kayla G Sprenger

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jonathan G FarisDepartment of Chemical and Biological Engineering, University of Colorado Boulder, Boulder, CO, United States.
Daniel OrbidanDepartment of Chemical and Biological Engineering, University of Colorado Boulder, Boulder, CO, United States.
Charles WellsDepartment of Computer Science, Rice University, TX, Houston, United States.
Brenden K PetersenComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Kayla G SprengerDepartment of Chemical and Biological Engineering, University of Colorado Boulder, Boulder, CO, United States.
University of Colorado Boulder · USLawrence Livermore National Laboratory · USRice University · US

Funding

Breaking the Barrier to an HIV VaccineDP1AI175471 · NIAID · UNIVERSITY OF COLORADO · PI Sara Sawyer · 2022 to 2026
$5.5M
Characterizing Host-Virus Interactions in a New HIV Model OrganismR01OD034046 · OD · UNIVERSITY OF COLORADO · PI Sara Sawyer · 2022 to 2026
$3.6M
Interdisciplinary Predoctoral Training in Molecular BiophysicsT32GM145437 · NIGMS · UNIVERSITY OF COLORADO · PI JOSEPH J FALKE · 2022 to 2026
$2.5M
Coupling Machine Learning with Agent-Based Modeling to Design a Universal Influenza VaccineR21AI169364 · NIAID · UNIVERSITY OF COLORADO · PI SPRENGER, KAYLA · 2022 to 2023
$412k
NIAID NIH HHS DP1 AI175471NIAID NIH HHS R21 AI169364NIGMS NIH HHS T32 GM145437NIH HHS R01 OD034046
6 · The paper itself

Abstract

Highly mutable infectious disease pathogens (hm-IDPs) such as HIV and influenza evolve faster than the human immune system can contain them, allowing them to circumvent traditional vaccination approaches and causing over one million deaths annually. Agent-based models can be used to simulate the complex interactions that occur between immune cells and hm-IDP-like proteins (antigens) during affinity maturation-the process by which antibodies evolve. Compared to existing experimental approaches, agent-based models offer a safe, low-cost, and rapid route to study the immune response to vaccines spanning a wide range of design variables. However, the highly stochastic nature of affinity maturation and vast sequence space of hm-IDPs render brute force searches intractable for exploring all pertinent vaccine design variables and the subset of immunization protocols encompassed therein. To address this challenge, we employed deep reinforcement learning to drive a recently developed agent-based model of affinity maturation to focus sampling on immunization protocols with greater potential to improve the chosen metrics of protection, namely the broadly neutralizing antibody (bnAb) titers or fraction of bnAbs produced. Using this approach, we were able to coarse-grain a wide range of vaccine design variables and explore the

Indexed as

AIDS VaccinesHIV-1HIV InfectionsAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesHumansAIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV Antibodiesaffinity maturationagent-based modellingdeep reinforcement learning (Deep RL)HIV - human immunodeficiency virusimmunovirologymultiscale (MS) modellingvaccine design protocol

Identifiers

PMID36405722
PMCPMC9670804
OpenAlexW4308101945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.